Composition for improving cognitive function, method for research of same, and research system
The use of opioid agonists to induce synchronized brain waves through epidermal biopotential measurement offers a non-invasive method for evaluating and improving cognitive function, addressing the limitations of existing cognitive evaluation methods and treatments for dementia.
Patent Information
- Application Number
- PCT/JP2024/017209
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-10
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods for evaluating cognitive function, particularly in humans and animals, are not simple or reliable, and existing treatments for cognitive decline associated with dementia lack effective non-invasive and universally applicable approaches.
A composition and system utilizing opioid agonists, such as κ-opioid agonists like nalfurafine and difelikephalin, that induce 40 Hz and 15-25 Hz synchronized brain waves by measuring epidermal biopotential, allowing for the development of preventive and therapeutic agents, functional foods, and cosmetics to improve cognitive function.
The system effectively induces synchronized brain waves, enhancing cognitive function by measuring epidermal biopotential and analyzing frequency bands, providing a non-invasive method for evaluating cognitive function and identifying compounds that improve cognitive performance.
Smart Images

Figure JPOXMLDOC01-APPB-M000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Compositions that improve cognitive function, methods for searching for the same, and search systems
[0001] The present invention relates to a composition that improves cognitive function in humans and animals, and a method and system for conveniently searching for compounds that improve cognitive function.
[0002] With the global aging society, assessment of cognitive function is an essential technique for the prevention and treatment of dementia, including Alzheimer's disease (AD). However, there are currently no simple and reliable methods for assessing cognitive function. The Mini-Mental State Examination (MMSE), which is a subjective assessment, is commonly used in humans (Non-Patent Document 1). Meanwhile, assessing cognitive function in animals is difficult, and mice are assessed by brain pathological changes, such as in App (amyloid precursor protein) knock-in mice (Non-Patent Document 2) and 5xFAD model mice (familial AD (FAD)) containing five mutations (Non-Patent Document 3). Thus, cognitive function cannot be assessed by simple and rapid physical examinations, blood tests, or tissue biopsy tests, which are problematic.
[0003] Recently, a new biomarker has been discovered: 40-Hz oscillations of gamma (γ) waves, a high-frequency component of the human electroencephalogram. Specifically, cognitive function in AD is characterized by a decrease in fast brain oscillations of gamma waves. Since this is related to cognitive function in AD, it has been reported that this could potentially be applied to the treatment of cognitive function. Animal experiments have shown that 40-Hz visual and auditory sensory stimuli reduce AD-related cognitive decline, amyloid plaque deposition in the brain, neurofibrillary tangle formation, and neuronal and synaptic loss. Furthermore, in human AD patients, 40-Hz visual stimuli with flickering light and 40-Hz auditory sine wave stimuli induce gamma waves in the brain (γ-synchronous waves), which have been shown to be effective in suppressing progressive cognitive decline (Non-Patent Document 4).
[0004] The term "synchronous waves" refers to brain waves observed when 40 Hz visual or auditory stimulation increases the power of nearby frequency bands, due to the fact that brain wave oscillations have the property of attracting periodic external stimuli close to their natural frequency. Since the neural circuits producing the 40 Hz oscillation are activated, if this continues, synaptic connections are strengthened, leading to improved cognitive function. Based on this, Gamma Entrainment Using Sensory Stimulation (GENUS) was devised and is considered one of the most promising approaches for treating AD patients in the future.
[0005] Rodriguez I etal., Cochrane Database of Systematic Reviews, 2021, Issue 7. Art. No.:CD010783, https: / / doi: 10.1002 / 14651858.CD010783.pub3.Sakakibara et al.,BMC Neurosci, 2019, 20:13, https: / / doi.org / 10.1186 / s12868-019-0496-6Afewerky et al.,Sci Rep, 2022, 12:1537, https: / / doi.org / 10.1038 / s41598-022-05568-2Manippa et al., Front.Aging Neurosci., 2022, 14:1095081., https: / / doi:10.3389 / fnagi.2022.1095081Miller et al.Neuron, 2018, 100(2):463-475.doi:10.1016 / j.neuron.2018.09.023.Lundqvist et al.,Nat. Commun., 2018, 9(1):394.doi:10.1038 / s41467-017-02791-8.Xu et al., PLoSONE, 2017, 12:e0172477.doi:10.1371 / journal.pone.0172477Wang et al.,Translational Psychiatry, 2020,10:230,https: / / doi.org / 10.1038 / s41398-020-00918-yZhou et al.,Nature Communication, 2019, 10:1523.doi:10.1038 / s41467-019-09234-6Chen et al., BMCBioinformatics, 2013, 14:128.doi:10.1186 / 1471-2105-14-128Blalock et al.,Proc Natl Acad Sci USA., 2004, 101(7):2173-8.doi:10.1073 / pnas.0308512100,Ravetti et al.,PLoS One, 2010, 13;5(4):e10153.doi:10.1371 / journal.pone.0010153.
[0006] As mentioned above, it has been shown that visual or auditory stimulation can induce specific synchronized brain waves in patients with cognitive impairment, and that this can be used as a treatment to improve cognitive function. The ability to induce synchronized brain waves through external sensory stimulation could be an innovative approach to treating neurodegenerative and neuropsychiatric disorders, but research and development into this field has only just begun. Attempts at therapeutic approaches using audiovisual devices are only just beginning to be explored, and at present, only visual or auditory stimulation has been reported. It is unclear what other stimuli besides audiovisual ones can induce synchronized brain waves.
[0007] Electroencephalography (EEG) is required to observe synchronized brain waves, but human EEG testing is generally performed in an EEG laboratory by attaching 8 to 21 silver-silver chloride electrodes to specific locations on the scalp, which is extremely time-consuming and limits the ability to continually examine synchronized wave induction from external stimuli. Furthermore, experimental EEG measurement in animals requires craniotomy to attach electrodes directly to the brain, making it a highly invasive method that is difficult to examine in animal tests and also makes it unsuitable for general use from the standpoint of research ethics.
[0008] Understanding what external stimuli and conditions induce synchronized waves related to cognitive function could lead to the development of methods to maintain and improve cognitive function, making an innovative contribution to the prevention and treatment of dementia, a major issue in our super-aging society.
[0009] Based on the idea that synchronized biological waves, including electroencephalograms, can be induced not only by visual or auditory stimulation but also by the stimulation of skin with a compound, the inventors developed a method for improving cognitive function by estimating the pharmacological action of the compound from the epidermal biopotential (EB) induced in mice by compound stimulation, and as a result, identified a compound that improves cognitive function.
[0010] The present invention relates to the following compositions, search methods, and systems: (1) A preventive drug, therapeutic drug, functional food, fragrance, and / or cosmetic for improving cognitive function, containing as an active ingredient an opioid agonist that induces 40 Hz and / or 15-25 Hz head EBs. The inventors have found that compounds can also induce synchronous waves of 40 Hz and 15-25 Hz. Note that although 40 Hz is used here, the 35-45 Hz band may also be included depending on measurement accuracy and individual differences.
[0011] (2) The preventive medicine, therapeutic medicine, functional food, fragrance, and / or cosmetic for improving cognitive function according to (1), wherein the opioid agonist is a κ-opioid agonist. As shown in the following examples, κ-opioid agonists have the effect of inducing synchronous waves of 40 Hz or 15 to 25 Hz, and therefore, a composition for improving cognitive function containing a κ-opioid agonist as an active ingredient can be provided.
[0012] (3) The preventive and / or therapeutic drug for improving cognitive function according to (2), wherein the active ingredient is nalfurafine or difelikefalin. As shown in the examples, nalfurafine and difelikefalin can induce synchronous waves of 40 Hz and 15 to 25 Hz.
[0013] (4) A method for searching for compounds that improve cognitive function in humans and animals, comprising measuring the epidermal biopotential (EB) of the head using patch electrodes, converting the measured EB into digital values, recording and storing the digital values, and analyzing the stored EB using a mathematical model. By measuring the epidermal biopotential (EB) of the head using patch electrodes, it is possible to measure synchronous waves, which makes it possible to easily search for compounds that improve cognitive function, which has been very difficult to find using animal models, etc.
[0014] (5) The searching method according to (4), characterized in that the mathematical model is constructed using a mathematical model using a statistical method or a machine learning method, and the fluctuations in the potential when measuring the epidermal biopotential are expressed as frequency power values or power density spectrum (PSD) values, and when the effect size calculated therefrom is 0.5 or more in absolute value, it is determined that there is an effect of improving cognitive function. By calculating the effect size, it is possible to capture fluctuations in the epidermal biopotential with high sensitivity.
[0015] (6) The searching method according to (4) or (5), characterized in that the frequency band of the head EB to be analyzed is 40 Hz and / or 15 to 25 Hz after electrocardiogram waveforms have been reduced and removed. By analyzing the 40 Hz frequency band, which is a biomarker related to cognitive function, and the 15 to 25 Hz frequency band, which is related to working memory, it is possible to search for compounds that have an effect of improving cognitive function.
[0016] (7) The method of (6), further comprising analyzing gene expression and determining that a compound that enhances the expression of at least one gene selected from the group consisting of GLIA2, GLIA3, GRID1, GRID2, GRIN2, LDHA, VSNL1, CACNG3, NEFM, NDUFV2, SV2B, and MYT1L has a cognitive function-improving effect. The above genes are known to be associated with cognitive function. By analyzing the expression of these genes, compounds with a high cognitive function-improving effect can be selected.
[0017] (8) A cognitive function assessment system consisting of an EB measurement device including an EB measurement contact electrode for measuring epidermal biopotential in humans or animals, an A / D converter for converting electrode signals, a microcontroller for controlling the functional blocks, data storage, and a BLE module for Bluetooth wireless communication, a device controller, and a cloud server equipped with a mathematical model for analysis. A system for measuring epidermal biopotential has never been used as a cognitive function assessment system before. This system allows for easy assessment of cognitive function.
[0018] (9) The system according to (8) for monitoring pathological conditions and / or drug responsiveness related to cognitive function in humans or animals. Since the cognitive function can be evaluated in humans or animals, it has become possible to evaluate pathological conditions and drug responsiveness.
[0019] Flow diagram of a compound discovery method using the Epidermal Biopotential Sensing System (EBSS). Block diagram and signal pathway diagram of the EBSS. A diagram of the effect size at each frequency of mouse head EB when the positive control substance capsaicin was administered. In the present invention, a "cognitive function improving effect" is determined when the effect size (Cohen's d) is 0.5 or greater, exceeding the hatched level. The 40 Hz gamma wave, which is the synchronous frequency for cognitive function improving effects, is indicated by a dotted frame. A diagram of the effect size at each frequency of mouse head EB when the evaluation test substances nalfurafine and pregabalin were administered. In the present invention, a "cognitive function improving effect" is determined when the effect size (Cohen's d) is 0.5 or greater, exceeding the hatched level. The 40 Hz gamma wave, which is the synchronous frequency for cognitive function improving effects, and the 15-25 Hz beta wave, which controls working memory, are indicated by dotted frames. In a test to examine the working memory enhancement effect in mice using a Y-maze exploration test, administration of nalfurafine (0.1 μg / kg) tended to increase working memory. A comparative graph showing the enhancement of expression of various glutamate receptors in human epidermal cells (keratinocytes) by three drugs (nalfurafine, zatolumilast, and donepezil). The vertical axis shows the fold increase in gene expression over untreated cells.
[0020] As shown below, we disclose a method for searching for compounds that improve cognitive function in humans or animals, in which EB is measured using a patch electrode and the effect size is calculated using a mathematical model based on the measured EB, and a system for use therein. Furthermore, we have discovered that opioid agonists have a cognitive function-improving effect using this search method, and we disclose a composition for improving cognitive function that contains this as an active ingredient.
[0021] The present inventors conducted extensive research based on previous reports that visual or auditory stimulation induces synchronous brain waves (Non-Patent Document 4). Surprisingly, they found that subcutaneous administration of specific compounds to the back of mice using EBSS induced synchronous 40-Hz gamma waves in the head EBs, which reflect cognitive function improvement. This indicates that compounds that improve cognitive function can be identified using the 40-Hz EBs induced after skin stimulation. In other words, 40-Hz EBs could serve as a digital biomarker for cognitive function improvement. Therefore, they evaluated two centrally acting drugs with unknown cognitive function-improving properties using this method and found that one of them could be selected as a compound with cognitive function-improving properties based on the difference in the effect size of 40-Hz gamma waves. Furthermore, they calculated the effect size for each frequency from the frequency power values using statistical methods and machine learning analysis using artificial intelligence (AI). They found that the magnitude of the effect size can be used as an index for cognitive function assessment.
[0022] Furthermore, to investigate the comprehensive pharmacological effects of the evaluation compound, human epidermal cells (keratinocytes) were treated with a drug, and then RNA was extracted from the cells and subjected to gene expression analysis (transcriptome analysis) using a microarray. From the gene expression profile obtained, bioinformatics enrichment analysis (gene ontology analysis and pathway analysis) was used to informatically extract the pharmacological effects that the evaluation compound may induce. It is an established evaluation technique that enrichment analysis of a group of genes whose expression changes due to an evaluation drug reflects the pharmacological effect of the evaluation drug. However, finding a match between the extracted gene group and the enrichment analysis results with the expected pharmacological action process requires the collection of relevant information and a certain amount of experience, and it is by no means easy to confirm the consistency that supports the present invention.
[0023] The use of normal human epidermal cells has important biological significance: they are normal cells, free from genetic abnormalities, and therefore suitable for comprehensive drug response studies (in contrast to established cultured cell lines, which are cancerous, genetically mutated cells, and drug responses are significantly affected by the mutated genes, making accurate evaluation impossible). Also, epidermal cells are developmentally of the ectodermal lineage, just like neurons, and so consistency in genetic responses can be expected.
[0024] The events expressed by enrichment analysis indicate that the compound being evaluated induces a large effect as EB in the living body, leading to the pharmacological action (phenotype) of the individual, which means that the bioelectric potential of a specific frequency of EB measured on the body surface can be linked to the expected pharmacological action. This type of evaluation of administered compounds by combining electrophysiological and molecular biological techniques has not been reported before, and this was achieved for the first time with the completion of the EBSS according to the present invention.
[0025] The frequency bands that serve as the reference for associating EB with disease are the human electroencephalogram (EEG), which is a typical bioelectric potential and has already been measured for various diseases and is highly reliable. Furthermore, it has long been known that the frequency band classification of human EEG can be extrapolated to animals and evaluated in mice, and the results obtained from animal experiments can be directly applied to humans.
[0026] To search for compounds with cognitive function-improving effects, the EBs of mice administered with a test compound can be measured using the EBSS of the present invention, and the effect size at a synchronous frequency of 40 Hz can be calculated. Furthermore, in vitro gene expression analysis using human epidermal cells can be used to confirm biological information related to the cognitive function improvement of the test compound (Figure 1).
[0027] When searching for substances that improve cognitive function, the method of administering the compound may be any method that can induce synchronized waves in the brain in vivo, such as subcutaneous administration, intradermal administration, transdermal administration, oral administration, pulmonary administration, nasal administration, eye drop administration, ear drop administration, intravenous administration, or intraperitoneal administration. Using this method, screening for compounds that improve cognitive function can be carried out with minimal invasiveness, simply, in a short time, and at low cost, without relying on highly invasive evaluation systems such as pathological techniques or behavioral pharmacological evaluation systems that require large-scale equipment.
[0028] When the compounds discovered in the present invention are used for human medical purposes, they can be used in the form of injections, oral preparations, nasal drops, eye drops, ear drops, suppositories, topical preparations (patches, tapes, ointments, emulsions, creams, sprays), etc. In particular, when applied to elderly people with cognitive impairments or people with cognitive disabilities, it is preferable to use them in a non-invasive, visualized dosage form such as a transdermal preparation or patch, since this allows the status of drug administration to be recognized.
[0029] Furthermore, when used as a fragrance or cosmetic, it can be applied to the skin or mucous membranes, and when used as a food, it can also be used as a functional food in a way that does not involve a decrease in activity due to component denaturation.
[0030] As confirmed in the examples below using capsaicin, which has a cognitive function-improving effect, this method allows the presence or absence of 40 Hz gamma wave synchronization to be linked by confirming the expression of genes necessary for cognitive function improvement. As a result, the cognitive function-improving effect of a compound can be evaluated simply by observing head EB frequency after compound administration. Until now, while capsaicin has been known to have cognitive function-improving effects, its 40 Hz gamma wave synchronization-inducing effect was unknown. Subcutaneous administration of capsaicin in the present invention has been shown to induce 40 Hz gamma wave synchronization, which can be interpreted as the mechanism of capsaicin's cognitive function-improving effect. This demonstrates that the administration of a compound with 40 Hz gamma wave synchronization-inducing effect can enhance cognitive function improvement. In other words, the effect can be enhanced by combining the conventionally known visual and auditory stimulation of 40 Hz gamma waves with chemical stimulation using drugs or foods that have cognitive function-improving effects.
[0031] Furthermore, as shown in this specification, it has been shown that stimulation of the body surface away from the head can also synchronize 40 Hz gamma waves (reflecting cognition) and 15-25 Hz beta waves (reflecting working memory) in the head, thereby improving cognitive function. Therefore, similar effects can be expected from physicochemical tactile stimulation such as acupuncture, moxibustion, acupressure, and magnetic patches, which are physical and chemical stimuli from the body surface. These can be used alone or in combination as means of improving cognitive function.
[0032] Improving cognitive function here means that memory retention and cognition of external information (how we feel, perceive, and think) become appropriate, along with the maintenance of working memory (one of the functions of the prefrontal cortex of the brain, the ability to temporarily store and process information necessary for tasks and actions). Improving cognitive function ensures that information is processed appropriately in the brain, leading to a more positive outlook on life.
[0033] Therefore, compounds having a cognitive function improving effect can be used for medical purposes such as the prevention, treatment, rehabilitation, etc. of dementia accompanied by short-term memory impairment, mild dementia / Alzheimer's dementia (MCI / AD), dementia with Lewy bodies (DLB), normal pressure hydrocephalus (iNPH), major depressive disorder (MDD), bipolar depression, post-traumatic stress disorder (PTSD), depression, acute stress disorder, cognitive dysfunction after cerebral infarction / stroke or brain trauma, cognitive dysfunction associated with neurodegenerative diseases such as Parkinson's disease, multiple system atrophy and multiple sclerosis, cognitive dysfunction associated with drug addiction or alcohol addiction, schizophrenia, etc.
[0034] Furthermore, in the present invention, subcutaneous administration of nalfurafine was measured to enhance not only 40 Hz but also 15-25 Hz beta waves, which are an index of working memory involved in cognitive function. It has been reported that working memory, which is part of cognitive function, is achieved and executed in the brain through the mutual reaction of gamma waves including 40 Hz and beta waves including 15-25 Hz (Non-Patent Documents 5 and 6), but there have been no reports yet on compounds that induce beta waves in cognitive function.
[0035] As demonstrated in the case of nalfurafine, the present invention also includes methods, systems, and compositions for searching for compounds with cognitive-improving properties using 15-25 Hz beta waves as an index. A method for searching for compounds that improve cognitive function using the synchronization-inducing effect of 15-25 Hz beta waves as an index, as well as 40 Hz gamma waves, is preferably recommended.
[0036] The present invention will be specifically explained below with reference to the following data, but the present invention is not limited to these.
[0037] [Animal Model and Measurement System] An animal model was used in the creation of the present invention. Hairless mice (Hos:HR-1, SPF, male, Japan SLC) were used as test animals to attach measurement electrodes to their skin, and EB was measured after subcutaneous administration of a drug to the mice. Because hairless mice have no body hair, electrodes can be attached non-invasively to any part of the body surface. In this example, since EB including electroencephalograms was to be detected, patch electrodes were attached to the head and head EB was measured. A reference electrode was attached to the tail. Figure 1 shows a flow diagram of the compound screening method.
[0038] The developed EBSS consists of a highly flexible electrode sheet (patch-type EB measurement electrode), a compact, lightweight EB measurement device capable of high-precision, low-noise EEG measurement, and a control unit. The patch electrodes are adhesive and can be directly attached to the skin epidermis. The patch electrodes and data integrated circuit are sensitive enough to measure extremely minute neuronal action potentials of less than 1 μV that are transmitted through the skull shield, enabling comprehensive measurement and collection of various biosignals from the body surface. Therefore, EB can comprehensively measure not only EEG potentials, but also myoelectric potentials, cardiac potentials, and other biosignals from other parts of the body. Because head EB comprehensively includes EEG and head tissue potentials, compound solvent control data are also collected during EB analysis, and the fluctuation potentials compared to the control group are analyzed (Figure 1, flow diagram of the synchronization frequency evaluation process).
[0039] Figure 2 shows the block diagram and signal path diagram of the EBSS. The EBSS consists of a highly flexible electrode sheet (EB measurement contact electrode), a small-signal measurement unit capable of measuring EEG with high accuracy and low noise despite its compact size and light weight, and a control tablet (device controller). The contact electrodes are patch-type electrodes that can be directly attached to the skin epidermis at multiple locations on the body surface for simultaneous measurement. The electrodes are formed on a flexible sheet and are attached to the body surface with high adhesion. The EB measurement electrodes (head, back, and control) are connected to an A / D converter via cables, which converts the analog measured voltage into a digital value. The digital signal is recorded in storage via a microcontroller that controls each functional block. The microcontroller is connected to a BLE module that receives control commands and transmits EB data via Bluetooth wireless communication and is controlled from the control tablet. The EB data recorded in the storage can be received by a control unit, such as a tablet, and transmitted to an external cloud server via the tablet's Internet connection. The cloud server is equipped with data analysis software, which performs the data analysis. The software also has a high-performance filter that can efficiently remove interference noise such as power supply noise and ECG noise. The highly accurate analysis results are reported to the user.
[0040] We describe the analysis of the measured and collected potential waveforms. The measured signal, head EB, is a bioelectric potential that includes electroencephalograms (EEGs). However, electrocardiograms (ECGs) generally have a high potential and are contaminated by EBs. Because ECGs have a significant impact on the measurement data, they were treated as interference signals and removed using the system's cardiac potential removal filter. Furthermore, potential waveform analysis was performed using a signal processing program based on an AI mathematical model developed specifically for this system. This program consists of processes for preprocessing, feature transformation, and effect size derivation. The mathematical model was constructed using statistical and / or machine learning techniques. The potential fluctuations during EB measurement were converted to frequency power values through noise reduction processing (preprocessing) using a filter, and these frequency power values were then converted to power density spectrum (PSD) values divided by frequency. By converting the data into frequency information such as frequency power values and PSD, the amount of change at characteristic frequencies can be treated as a digital biomarker.
[0041] To quantitatively compare the difference in frequency change between groups of individuals with different sensory reception, such as humans and animals, it is useful to quantify and output the difference in feature values between groups using an index called "effect size," which is an index that represents the degree of standardized effect without relying on data units. Effect size is a preferable concept for quantifying sensory response. Artificial intelligence (AI) is used to analyze the feature values obtained by this method, and further learning can optimize the mathematical model and improve performance.
[0042] [EB Data Analysis] The waveform data of a single channel measured with a patch electrode was subjected to fast Fourier transform, and the horizontal axis represents frequency (Hz) and the vertical axis represents signal power (μV 2 In the analysis, to confirm the difference in frequency spectra before and after drug administration under each administration condition, one minute of data was extracted as a reference value before and after drug administration, and spectra were extracted every 10 seconds and averaged (epoch) to obtain data before and after administration.
[0043] In this study, EBs in the frequency band of 0 to 60 Hz were observed, but human EEGs referred to as disease-related EBs are classified into delta waves (1 to 4 Hz, slow waves), theta waves (4 to 7 Hz, slow waves), alpha waves (8 to 13 Hz), beta waves (15 to 30 Hz, fast waves), and gamma waves (30 to 80 Hz). In the literature, these frequency bands are often treated as similar oscillation frequency bands in animal tests, and can be used as disease-related EBs.
[0044] [Determination by effect size (Cohen's d)] To determine the effect size of a biological response, determination was made using the effect size of Cohen's d. Determination by the effect size of Cohen's d is an index that represents the degree of a standardized effect, independent of the unit of data, and is a standardized index that does not change depending on the sample size. Therefore, this is an analysis method suitable for cases such as this test, where there are individual differences in the sensory amount of mice and the mean values in the sample data are different. Cohen's d is also an index of effect size that is used in psychological evaluations where there is a large individual difference. It is said that even if the mean values are different, there will be differences in the effect if the standard deviations are different, and this is expressed by the following formula.
[0045] The calculated value indicates how far the average value is in units of standard deviation (it can also indicate the direction as a positive or negative effect), and as shown below, an absolute value of d exceeding 0.8 is interpreted as a "large effect." In the examples of the present invention, the effect size of the responsiveness evaluation was calculated as an absolute value, and a value of 0.5 or more (moderate effect) was considered to be an effect with significant variation. d = 0.2 → small effect d = 0.5 → medium effect d = 0.8 → large effect d = 1.2 → very large effect d = 2.0 → extremely large effect
[0046] [Detection of 40 Hz Synchronized EBs by Administration of a Standard Compound] First, to verify the concept of the present invention, that subcutaneously administered compounds induce 40 Hz synchronized gamma waves in the brain, which are an indicator of cognitive function improvement, we selected the research reagent capsaicin. Capsaicin is known as the main component that gives chili peppers their spiciness, and has been reported to reduce AD-related brain phosphorylated tau protein in rats (Non-Patent Document 7) and to reduce Aβ load in the brain and restore cognitive decline in AD model mice (APP / PS1) (Non-Patent Document 8).
[0047] As shown in Figure 3, capsaicin was administered subcutaneously to the back of mice (10 μg / kg, 50 μL s.c. / site, n=6). The effect size of head EBs at each frequency was calculated using the EBSS. The largest peak was detected at 40 Hz. According to Cohen's d, an effect size of 1.06 is considered a "large to very large" effect. This indicates that head EBs at 40 Hz measured during subcutaneous administration of the compound function as a digital biomarker for improving cognitive function.
[0048] [Detection of synchronized EBs following administration of compounds with unknown effects on cognitive function] Next, we evaluated two drugs that act on the central nervous system but whose effects on cognitive function are unknown: nalfurafine ((2E)-N-[(5R,6R)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(furan-3-yl)-N-methylprop-2-enamide monohydrochloride (IUPAC), mouse dose 10 μg / kg, 50 μL s.c. / site), a drug used to treat intractable pruritus, and pregabalin (mouse dose 10 mg / kg, 50 μL s.c. / site), a drug used clinically to treat neuropathic pain (Table 1). Both of these drugs act centrally and have clinical doses set for humans, so subcutaneous stimulation can be performed at an appropriate dose that does not cause toxicity (a dose that can exert only the main pharmacological effect).
[0049]
[0050] Each drug was administered subcutaneously to the dorsal lateral region of eight mice per group, and head EBs were monitored for 10 minutes after administration. Figure 4 shows the effect size of head EBs following administration of the two drugs. At 40 Hz, a digital biomarker of cognitive function, nalfurafine achieved an effect size of 0.66 (Cohen's d = moderate to large effect), indicating an improvement in cognitive function. Furthermore, beta waves in the 15-25 Hz range, an index of working memory involved in cognitive function, were measured to be enhanced with effect sizes ranging from 1.41 to 0.77 (large effect). Working memory is also part of cognitive function.
[0051] In addition to its main pharmacological effect, antipruritic, nalfurafine has been reported to cause "insomnia" as a side effect of psychoneurological effects. However, since insomnia also awakens consciousness, it can be interpreted as working to improve cognitive function.
[0052] On the other hand, at 40 Hz when pregabalin was administered, the effect size was 0.07, and it was determined to have no effect (Cohen's d = no effect). Pregabalin's side effect information states that "dizziness" and "somnolence," which are symptoms opposite to those related to cognitive function, frequently occur. Measurements of head EB showed effect sizes of 1.25 to 1.16 (very large effect) from 5 to 10 hours, centered on theta waves, which reflect sleep. No significant effects were observed at 15 to 25 Hz or 40 Hz. These results indicate that nalfurafine has an effect of improving cognitive function, while pregabalin does not.
[0053] [Working Memory Assessment Test in Mice] Y-maze exploration in mice is a test to assess spatial working memory, utilizing the tendency to enter a different arm from the one previously entered. Male ddY mice (5-7 weeks) were used, and the drugs used were saline and nalfurafine (subcutaneously administered at two doses: 0.01 μg / kg and 0.1 μg / kg). Enhancement of working memory was assessed by the rate of spontaneous exchange behavior ([number of three consecutive entries into different arms × 100 / [total number of arm entries − 2]) during movement through the Y-maze after drug administration. As shown in Figure 5 , administration of nalfurafine (0.1 μg / kg) tended to increase working memory. This was considered a significant response for a centrally acting drug that has a sedative effect at high doses. This result is consistent with the induction of 15-25 Hz beta waves, which reflect working memory, by nalfurafine.
[0054] [Transcriptome analysis in human keratinocytes] Transcriptome analysis is a comprehensive gene expression analysis that analyzes gene groups expressed in response to stimuli received by cells, and the pharmacological effects on cells can be estimated from the function of genes that have changed. In the case of pharmaceuticals, this reflects the entire pharmacological action, including efficacy and side effects, and is an extremely useful method for comprehensively investigating molecular biological effects. Specific biological responses can be determined from gene expression data by performing enrichment analyses such as ontology analysis and pathway analysis.
[0055] In this study, human epidermal keratinocytes (NHEK-Ad, Lonza, Tissue Acquisition No. 38137) were used to examine the compound responsiveness to subcutaneous stimulation. The cells were cultured at 2 × 10 in serum-free cell culture medium (KGM-Gold™ Bullet Kit, Lonza). 5 The cells were seeded in a 6-well culture plate at 2 mL / well, and incubated under CO 2 In an incubator (37°C, 5% CO 2After overnight culture, the medium was removed from the 6-well culture plate, and the plate was washed with ice-cold D-PBS(-). Total RNA was then extracted using an RNA extraction kit (RNeasy™ Plus Mini Kit, QIAGEN).
[0056] Human mRNA transcriptome analysis was performed using a microarray (3D-Gene mRNA Oligo chip, AROS (trademark) equipped with 24,460 probes, Toray) according to the method specified by the manufacturer.
[0057] The results of the microarray analysis are output as the expression levels of approximately 22,000 types of genes, and bioinformatics tools are used to estimate pharmacological effects from the induced gene groups. In this study, the top 500 genes with the highest amplification rates were analyzed.
[0058] Typically, gene ontology analysis (Gene Ontology-Biological Process: GO-BP) and pathway analysis related to the expression of biological effects can comprehensively extract biological effects, including pharmacological effects to which cells respond. The GO-BP analysis in this study used Metascape (Non-Patent Document 9), a proven analytical tool used in the majority of research papers.
[0059] First, because 40 Hz gamma waves were observed with nalfurafine, we confirmed whether common GO-BPs related to cognitive function were identified in nalfurafine as well as in capsaicin, a reference compound for improving cognitive function. As a result, as shown in Table 2, 18 of the 144 GO-BPs identified in capsaicin were also common to nalfurafine, and 11 of these were related to cognitive function, such as neuronal excitation (transmembrane transport of ions), synaptic transmission, cell-cell interactions (homeostasis), and behavioral reflection. GO-BPs related to cognitive function improvement similar to those in capsaicin were identified in nalfurafine.
[0060]
[0061] Furthermore, when comparing the centrally acting drugs nalfurafine and pregabalin, in the neuropsychiatric GO-BPs (top three extracted and listed), nalfurafine was identified as having a higher-ranking GO-BP of "brain development" in addition to "modulation of chemical synaptic transmission," which is related to its clinical antipruritic effect, suggesting that nalfurafine has an effect of supporting cognitive function (Table 3).On the other hand, for pregabalin, only a GO-BP representing its clinical pharmacological effect of analgesia was identified, and no biological processes related to cognitive function could be extracted.
[0062]
[0063] Next, pathway analysis was performed using Enrichr (Non-Patent Document 10), a well-established web tool. Table 4 lists the top three pathways extracted from the results of the Enrichr-Elsevier Pathway Analysis. For nalfurafine, the pathway related to "involvement of TCA cycle enzymes in Alzheimer's disease" was extracted at the top, indicating that pathways related to the pathology of AD are active. When combined with the GO-BP results in Table 3, nalfurafine can be interpreted as having an effect on the pathology of AD by inducing gene expression in a direction that promotes brain development and improving cognitive function. As described above, the gene expression enrichment analysis strongly suggested that nalfurafine has an effect of improving cognitive function.
[0064]
[0065] Furthermore, to confirm the cognitive improvement effects of nalfurafine using gene expression profiles, we compared it with two existing drugs with confirmed cognitive improvement. Donepezil, a cholinesterase (ACHE) inhibitor, has been approved for the treatment of Alzheimer's disease and dementia with Lewy bodies and is effective in improving cognitive function. Zatolmilast, a phosphodiesterase 4D (PDE4D) inhibitor, is being developed in Japan and the United States as a cognitive improvement drug for Fragile X syndrome (a genetic disease associated with developmental delay / intellectual disability) and Alzheimer's disease, and has shown effective results in clinical trials. Although these two drugs have different mechanisms of action, it is reasonably assumed that the events that activate neurons and improve cognitive function involve promoting the excitatory neurotransmitter glutamate and its receptors in intracellular pathways.
[0066] From this perspective, we analyzed the enhanced expression of glutamate receptors in human keratinocytes (keratinocytes derived from the same ectodermal system as the nervous system) exposed to nalfurafine, donepezil, and zatolumilast (final concentrations of 1 μM each), and observed similar profiles, as shown in Figure 6. In particular, nalfurafine binds to GRIA2 (glutamate ionotropic receptor AMPA type subunit 2, NCBI-GeneID: 2891), GRIA3 (glutamate ionotropic receptor AMPA type subunit 3, NCBI-GeneID: 2892), GRID1 (glutamate ionotropic receptor delta type subunit 1, NCBI-GeneID: 2894) and GRIN2D (glutamate ionotropic receptor NMDA type subunit 2, NCBI-GeneID: 2895). 2D, NCBI-Gene ID: 2906), and the expression profile was similar to that of donepezil and zatolumilast. This suggests that, although the initial sites of action are different, the three drugs share similarities in the intracellular process of their cognitive function-improving effects, namely, glutamate-mediated neuronal excitation. The cognitive function-improving effects of nalfurafine are also supported by these experimental results.
[0067] In addition, the results of individual gene expression strongly support the fact that nalfurafine has the effect of improving cognitive function. The mechanism of action of donepezil, whose clinical effectiveness as a cognitive function improving drug has been confirmed, is ACHE inhibition, and the mechanism of action of zatolumilast is PDE4D inhibition. Although enzyme inhibitory activity and drug-responsive gene expression are not synonymous, they are related as intracellular events. Therefore, when the gene expression levels of ACHE and PDE4D for these three drugs in keratinocytes were examined, the results were as shown in Table 5, and nalfurafine showed a tendency to suppress (i.e., a tendency to inhibit) the genes that are target molecules of both donepezil and zatolumilast.
[0068]
[0069] Next, gene expression analysis has revealed that nalfurafine also activates genes that control cognitive function in Alzheimer's disease. Specifically, it has been reported that 48 genes (50 probes) were abnormally expressed in the hippocampus (memory formation site) of brain specimens from Alzheimer's disease (AD) patients (22 AD patients vs. 9 healthy controls, Non-Patent Documents 11, 12). Of these 48 AD-related genes, 18 genes (ATP6V0E1, C10orf76, CDK19, CSF1, DLG5, FCAR, FOXO1, FYCO1, HBEGF, ITGB5, LRP10, MCL1, RASL12, RND2, SERTAD2, TTN, ZBTB20, ZHX3) were upregulated, and 30 genes (ADGRL1, ASTN1, ATP5C1, BCL11A, CACNG3, CAMK1G, CAPRIN2, COX6A1, FAR2, FRY, LD) were downregulated. B2, LDHA, MYT1L, NDUFV2, NEFL, NEFM, NETO2, NRXN1, OPA1, PLCB1, PPIA, PPP3CA, RALYL, SERPINI1, SLC25A12, SNRK, SV2B, TAGLN3, TRIM36, VSNL1), and when the diseases associated with these gene groups were examined in the database (Enrichr-DisGeNET), it was found that, as shown in Table 6, all of the gene groups suppressed in the brains of AD patients are strongly involved in neuropsychiatric disorders. In other words, this means that the suppressed gene groups are causing cognitive dysfunction, and it can be understood that drugs that restore or amplify these suppressed gene groups will have an effect on improving cognitive function.
[0070]
[0071] In the examples of the present invention, when the gene group that changed by ±20% or more in nalfurafine-treated keratinocytes was examined, 22 of 48 AD-related genes were found to be affected, and half of these, 11 genes, showed expression patterns opposite to those in AD patients. The gene group that is down-regulated in the hippocampus of AD patients is highly likely to be the cause of cognitive impairment, and nalfurafine particularly increased the expression of three genes involved in the metabolism and excitation of neurons: LDHA, VSNL1, and CACNG3 (Table 7). LDHA (lactate dehydrogenase A) is a lactate-pyruvate interconverting enzyme involved in the production of pyruvate, a material in the TCA cycle that produces intracellular energy; VSNL1 (visinin-like 1) is a neuronal calcium sensor protein that is specifically expressed in the brain and is involved in signal transduction; and CACNG3 (calcium channel, voltage-dependent, gamma subunit 3) is an AMPA receptor regulatory protein (TARP) that is specifically expressed in the brain and controls both AMPA receptor transport and channel gating, promoting targeting to cell membranes and synapses. Induction of expression of these three genes promotes energy supply via the TCA cycle in the hippocampus and neuronal excitation via calcium ion influx, suggesting cognitive function activation, and is thought to be related to the mechanism of action of nalfurafine for improving cognitive function. Incidentally, LDHA expression was also enhanced by donepezil (1.35-fold increase in expression) and zatolumilast (1.51-fold increase in expression), which have been clinically confirmed to improve cognitive function. These results indicate that nalfurafine, like donepezil and zatolumilast, can be used as a cognitive function improver.
[0072]
[0073] [Confirmation of Common Properties of κ-Opioid Agonists] As described above, opioid compounds such as nalfurafine have been shown to have cognitive function-improving effects. However, considering the properties of opioid receptors, mu (μ)-opioid agonists such as morphine, which inhibit the production and release of neurotransmitters, are theoretically unlikely to have cognitive function-improving effects and are therefore not considered. Because nalfurafine is a kappa (κ)-opioid agonist, other κ-agonists are also likely to have cognitive function-improving effects.
[0074] To confirm the common properties of kappa opioid agonists, the pharmacological properties of difelikephalin (4-Amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl) piperidine-4-carboxylic acid acetate (JAN)) were also investigated. In normal human keratinocytes exposed to difelikephalin, the "complement activation in Alzheimer's disease" pathway was detected by Enrichr-Elsevier Pathway Analysis, demonstrating its cognitive function-modifying properties. Furthermore, an inhibitory effect on the expression of phosphodiesterase 4D (expression ratio 0.63) was also observed.
[0075] Furthermore, as summarized in Table 8, difelikefalin showed a gene expression response similar to that of nalfurafine (response in Table 6) in terms of responsiveness to 22 AD-related genes, and since it has the ability to amplify six genes whose expression is suppressed in the hippocampus of AD brains, it is expected to have an effect of improving cognitive function.
[0076] As described above, κ-opioid agonists commonly have the effect of amplifying cognitive function and can be used as cognitive function improving drugs. Examples of κ-opioid agonists include YNT-1612, difelikefalin (CR845), CR665 (FE200665), NP-5497-KA, MP11041, HSK21542, GR89696, U69593, SALVINORIN A, and EOM SALVINORIN B.
[0077]
[0078] Delta opioid agonists also have a pharmacological effect of improving depression, and are therefore thought to have a similar effect of improving cognitive function. Specific examples include SNC80, BW373U86, DPI-287, AZD2327, KNT-127, and NC-2800.
[0079] From the perspective of the group of genes whose expression is enhanced, compounds that enhance the expression of at least the genes GRIA2, GRIA3, GRID1, GRIN2D, LDHA, VSNL1, and CACNG3, which contribute to the cognitive function-improving effect of nalfurafine, and the genes NEFM, NDUFV2, SV2B, and MYT1L, which contribute to the cognitive function-improving effect of difelikefalin, can also improve cognitive function.
[0080] The cognitive function improving compounds identified in this embodiment include compounds disclosed herein that have a 40 Hz gamma wave synchronizing effect, compounds that have a 15-25 Hz beta wave synchronizing effect, kappa opioid agonists, delta opioid agonists, and opioid compounds that increase the expression of one or more genes selected from the gene group GRIA2, GRIA3, GRID1, GRIN2D, LDHA, VSNL1, CACNG3, NEFM, NDUFV2, SV2B, and MYT1L.
[0081] The EBSS used here consists of a group of small devices, including patch electrodes and a signal amplification and recording device, small enough to fit in a bag, eliminating the need for extensive experimental equipment. Evaluation time is also short; compound evaluation can be completed in approximately 30 minutes for one test condition, allowing a single course of experiment using several dozen mice to be conducted in one day, and including analysis time, the entire experiment can be completed in approximately one week. These advantages make it simple, space-saving, and time-saving for the research and development of pharmaceuticals and other products that involve animal evaluation, resulting in high cost-effectiveness. Furthermore, because evaluation costs are lower than those of conventional animal testing, it can also be used to screen foods and other products that prevent cognitive decline. This allows for the easy identification of compounds with cognitive function-improving properties. Therefore, preventive drugs, therapeutic drugs, functional foods, fragrances, and cosmetics for improving cognitive function can be created using the discovered compounds as active ingredients.
Claims
1. Preventive drugs, therapeutic drugs, functional foods, fragrances, and / or cosmetics for improving cognitive function that contain as active ingredients opioid agonists that induce 40 Hz and / or 15-25 Hz head EBs.
2. A preventive drug, therapeutic drug, functional food, fragrance, and / or cosmetic for improving cognitive function according to claim 1, characterized in that the opioid agonist is a κ opioid agonist.
3. A preventive and / or therapeutic drug for improving cognitive function according to claim 2, wherein the active ingredient is nalfurafine or difelikefalin.
4. A method for discovering compounds that improve cognitive function in humans and animals, comprising measuring the epidermal biopotential (EB) of the head using a patch electrode, converting the measured EB into digital values, recording and storing the digital values, and analyzing the stored EB using a mathematical model.
5. The searching method according to claim 4, characterized in that the mathematical model is constructed using a statistical method or a machine learning method, the fluctuation in potential when the epidermal biopotential is measured is expressed as a frequency power value or a Power Density Spectrum (PSD) value, and when the effect size calculated therefrom is an absolute value of 0.5 or more, it is determined that there is an effect of improving cognitive function.
6. A searching method according to claim 4 or 5, characterized in that the frequency band of the head EB to be analyzed is 40 Hz and / or 15 to 25 Hz after electrocardiogram waveforms are reduced and removed.
7. The method of claim 6, further comprising analyzing gene expression and determining that a compound that enhances the expression of at least one of the genes GLIA2, GLIA3, GRID1, GRID2, GRIN2, LDHA, VSNL1, CACNG3, NEFM, NDUFV2, SV2B, and MYT1L has an effect of improving cognitive function.
8. A cognitive function assessment system for humans or animals, comprising an EB measurement device including an EB measurement contact-type electrode for measuring epidermal biopotentials, an A / D converter for converting electrode signals, a microcontroller for controlling functional blocks, and a BLE module for data storage and Bluetooth wireless communication, a device controller, and a cloud server equipped with a mathematical model for analysis.
9. The system according to claim 8 for monitoring cognitive pathology and / or drug responsiveness in humans or animals.
Citation Information
Patent Citations
Compositions and methods for treating neurological disorders
JP2018531926A
